New Delhi India January 26 ANI The regular market approval from Drugs Controller General of India DCGI to COVID-19 vaccine Covishield and Covaxin is expected to be done soon but only after price fixation is complete, official sources told ANI on Wednesday.
The National Pharmaceutical Pricing Authority NPPA DCGI, Drug regulators and senior officials of the Union Health Ministry recently held a meeting about fixing the prices of Covishield and Covaxin, but no final decision has been made yet.
It is expected that the price of a vaccine will be lower than Rs 275 per dose and additional service charges of 150 per dose to make both vaccines affordable for all.
According to the earlier information provided by the Central Drugs Standard Control Organisation CDSCO Subject Expert Committee SEC of CDSCO, the DCGI will give its decision on Covishield and Covaxin status from restricted use in emergency situations to grant new drug permission with conditions in the adult population. The Serum Institute of India SII and Bharat Biotech both applied for market approval for Covishield and Covaxin in December 21.
The subject expert committee asked both vaccine manufacturing companies to submit more data before they can give market approval.